⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
11,055
Total Claims
$9.3M
Drug Cost
1,093
Beneficiaries
$8,498
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+116%
Cost per patient vs peers
$8,498 vs $3,933 avg
+42%
Brand preference vs peers
72.5% vs 51.2% avg
Brand vs Generic
28% generic
Brand: 7,245 claims · $9.1M
Generic: 2,748 claims · $57K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Mifepristone | 36 | $1.5M |
| Semaglutide | 1,035 | $1.2M |
| Empagliflozin | 941 | $979K |
| Dulaglutide | 729 | $874K |
| Insulin Aspart | 434 | $656K |
| Insulin Glargine,hum.Rec.Anlog | 551 | $493K |
| Insulin Lispro | 323 | $455K |
| Tirzepatide | 342 | $394K |
| Insulin Regular, Human | 125 | $297K |
| Insulin Detemir | 242 | $290K |
| Insulin Degludec | 157 | $219K |
| Insulin Degludec | 265 | $202K |
| Insulin Glargine,hum.Rec.Anlog | 159 | $141K |
| Semaglutide | 70 | $120K |
| Insulin Glargine,hum.Rec.Anlog | 179 | $113K |
Prescribing Profile
Patient Profile
68
Avg Age
61%
Female
1.96
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About